It is now clear that a significant degree of gene expression dysregulation in cancer occurs post-transcriptionally i. RNA Binding Proteins RBPs are the main post-transcriptional regulators of gene expression, controlling all aspects of the RNA life cycle such as processing, modification, transport, translation, and decay.
However, it is still largely unclear how different RBPs are dysregulated during the course of cancer progression, in order to promote different aspects of malignancy. In particular, they are experts in Mass Spectrometry MS based proteomics, using various MS techniques to quantitatively study processes such as protein translation and RNA-Protein interactions, as well as combining proteomics data with RNA-sequencing to reveal the intricacies of post-transcriptional regulation by RBPs.
Crucially, recent advances in RNA therapeutics mean that a more mechanistic understanding of RBPs contribution towards malignancy can potentially be used to develop novel therapies for tackling different cancers. Visit Dr Mardakheh's profile page. Dr Prabhakar Rajan 's lab UroSplice Group are studying how alternative splicing and RNA-binding proteins impact on prostate cancer phenotypes, and identifying new prostate cancer RNA biomarkers of disease progression.
The group's main interests lie in the transcriptional and post-transcriptional regulation of alternative splicing, and the impact thereof on cancer-related splicing events underlying key biology. They are exploring novel links between splicing regulation and the tumour microenvironment following key genomic changes in prostate cancer. Visit Dr Rajan's profile page.
Increased genomic and transcriptomic sequencing have revealed that, through various means, mRNA splicing is altered in cancer. Mutations or changes in expression levels of splicing factors SF and RNA binding proteins RBPs can lead to dysfunctional gene splicing and activation of oncogenic pathways. Mutations in splicing factors are frequent across cancers, with the SF3B1 gene being the most commonly altered. Altogether alteration in SFs and RBPs promote a general acceptance that aberrant splicing is a pan-cancer hallmark that drives disease progression.
Visit Dr Rouault-Pierre's profile page. The miRNA-silencing regulatory pathway impinges on aspects of cell biology and organism physiology. Approx 20 minute walk from Whitechapel campus. How to get to the Mile End campus.
The School will be situated in Malta about km off the coast of Italy with a population of just under half a million. The official languages of Malta are English and Maltese, although most people speak English. The islands enjoy a pleasantly warm and sunny climate all year round with hot summers. This state of the art, purpose-built school located next to Victoria on Gozo will sit alongside a modern newly built Gozo Hospital.
Home Back to home. Study Areas of study Foundation courses Biological and biomedical sciences Business and management Chemical sciences Comparative literature Computer and data science Dentistry Drama Economics and finance Engineering English Film studies Geography and environmental science Global health and development History Law Linguistics Materials science Mathematics Medicine Modern languages and cultures Physics and astronomy Politics and international relations Psychology.
Our ultimate goal is to provide the foundation for innovative diagnostic and therapeutic modalities based on lncRNAs to improve the way we diagnose and treat cancer.
The research will use clear cell renal cell carcinoma ccRCC; the most common type of kidney cancer in adults as a model system to investigate the significance of lncRNAs in cancer. To execute this project, Dr Stojic has teamed up with several basic and clinical scientists in the UK and abroad. In collaboration with Professor Igor Ulitsky Weizmann Institute of Science, Israel the team will also explore conserved sequence elements within lncRNAs that may be involved in the maintenance of genome stability.
With RNA-based approaches representing an expanding class of therapeutics, Dr Stojic and her team hope that this work may pave the way for the development of new RNA-based strategies to improve diagnosis and treatment of cancer.
0コメント